Behind the Scenes: Building a Robust Scientific Program at the AACR Annual Meeting
In our first post of this Behind the Scenes series, you read about the years of planning that go...
In our first post of this Behind the Scenes series, you read about the years of planning that go...
When the AACR Annual Meeting 2015 begins April 18 in Philadelphia, more than 18,500 attendees will flow seamlessly through...
Guest Post by Matthew J. Sikora, PhD University of Pittsburgh Cancer Institute
Advances against cancer that make it to the clinic are a result of many years of hard work by...
The rapid fire of U.S. Food and Drug Administration (FDA) approvals of new treatments for cancer continued last week...
When the hottest minds in cancer genomics meet the hottest minds in computational and systems biology, you can rest...
Guest Post by Anees B. Chagpar, MD, MPH, MBA Yale Cancer Center
Adding the PI3-kinase inhibitor pictilisib to fulvestrant doubled progression-free survival for some women with advanced hormone-receptor positive breast cancer,...
After making great strides for some patients with melanoma and lung cancer, immunotherapy drugs are starting to offer hope...
SABCS co-chair and AACR President Carlos L. Arteaga, MD, shares his views on this year's symposium and what the...